Ahmed Naguy, Nadyah Alayadhi, Saxby Pridmore, Bibi Alamiri
{"title":"维洛沙嗪治疗一名过度运动自闭症儿童的早期阳性报告。","authors":"Ahmed Naguy, Nadyah Alayadhi, Saxby Pridmore, Bibi Alamiri","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Herein, authors report on an ASD child with comorbid ADHD, ID, metabolic syndrome and nocturnal enuresis that failed multiple trials of psychotropic agents for behavioural dyscontrol. Viloxazine adjuventia brought about remarkable improvement spanning different domains. Purported pharmacodynamic mechanisms are briefly discussed. This case represents one of the earliest reports of viloxazine use in ASD.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 1","pages":"89-92"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626922/pdf/","citationCount":"0","resultStr":"{\"title\":\"Early Positive Report of Viloxazine for a Child with Hyperkinetic Autism.\",\"authors\":\"Ahmed Naguy, Nadyah Alayadhi, Saxby Pridmore, Bibi Alamiri\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Herein, authors report on an ASD child with comorbid ADHD, ID, metabolic syndrome and nocturnal enuresis that failed multiple trials of psychotropic agents for behavioural dyscontrol. Viloxazine adjuventia brought about remarkable improvement spanning different domains. Purported pharmacodynamic mechanisms are briefly discussed. This case represents one of the earliest reports of viloxazine use in ASD.</p>\",\"PeriodicalId\":94351,\"journal\":{\"name\":\"Psychopharmacology bulletin\",\"volume\":\"55 1\",\"pages\":\"89-92\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626922/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychopharmacology bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology bulletin","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Early Positive Report of Viloxazine for a Child with Hyperkinetic Autism.
Herein, authors report on an ASD child with comorbid ADHD, ID, metabolic syndrome and nocturnal enuresis that failed multiple trials of psychotropic agents for behavioural dyscontrol. Viloxazine adjuventia brought about remarkable improvement spanning different domains. Purported pharmacodynamic mechanisms are briefly discussed. This case represents one of the earliest reports of viloxazine use in ASD.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
